Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. - Wikidata - wikimedia - TriplyDB

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

http://www.wikidata.org/entity/Q36203402

about

Commentary on the MID3 Good Practices Paper.Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds.Crowdsourced Asparagus Urinary Odor Population Kinetics.Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model.Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics.Development and performance of npde for the evaluation of time-to-event models.Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.Population Pharmacokinetics of Tacrolimus in Children with Nephrotic Syndrome.Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status.Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models

P2860

Q38707591-E8613568-FABF-4E8C-AF75-B9385C1035E0 Q38722944-222E16B4-7B89-49BE-A557-97E03C6A99EF Q38790140-7159F100-786D-4F8B-A806-2A7427A960E4 Q45948812-9D618617-D0E3-488D-B179-1097829E9923 Q47131961-7B4A7BCB-4AF8-4539-A8FB-3BD1BABC8026 Q47138419-3FE95200-EEA1-4A9C-A3FD-B398A5A19E50 Q47219276-E339B19C-57E9-4604-A764-1ACF40CC8F97 Q48170803-2A2AC4E6-93DD-48C6-8FD2-F8C97C26331C Q48249281-E1162C37-FFAC-45A8-BCB4-DA141E54C9CF Q50079226-CC9BB89D-ACFD-4645-87B4-E42D61B9D6A0 Q52594698-40562207-4470-453A-B807-94367B167E1D Q55470248-21AF26FB-BF02-4F20-9844-A8B83E62A0FD Q57059911-ACF5F397-85C4-4B8F-845E-CF312BB11286 Q58752746-C41A7378-6FB5-4B60-B8CD-BE41867656B5 Q58752749-AD43774A-A418-4E3E-9821-317450F6A9FF

P2860

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

http://www.wikidata.org/entity/Q36203402

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

@ast

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

@en

type

label

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

@ast

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

@en

prefLabel

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

@ast

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

@en

P1433

Q36203402-B8CB9ADC-8698-4426-8AA2-359D159E1A3A

P1476

Q36203402-9FAE0CB6-FFDC-436C-BF0B-2D3EC0DBB4B6

P2093

Q36203402-29D5498E-8EEC-4197-B85F-B1A59941E0B9

Q36203402-4D5B0FA2-33C1-4EEB-B57E-5251A86F10E2

Q36203402-7C084E05-B15D-4B65-944F-0966AACD77DC

Q36203402-7C8FDA42-662D-4E01-8AE5-285025CC93BC

Q36203402-887E8316-3682-40A8-8542-0851830E41AF

Q36203402-8D93BD65-5066-453C-A4DD-10FC06CB8444

Q36203402-9482675B-650F-4794-9AA1-B7502F8F99A4

Q36203402-A0951ECB-5CDF-4694-A41C-49E8CBF10ECD

Q36203402-AC889EDF-E21C-4573-A718-0622DD2F770C

Q36203402-CBF44984-9DCC-4246-A8C8-5FF4CB5CDB67

P2860

Q36203402-05630067-81A3-4F0B-A7C2-07C136688E83

Q36203402-07E36D06-F7E2-4EA3-AFEA-B3E23C698D2B

Q36203402-0DDFAC18-2EBC-4195-ACDA-7C17F13A0232

Q36203402-17033D42-EFDD-42DE-872D-0820AE720895

Q36203402-1CB003FD-45A8-43F9-B097-0B3FEE476CB7

Q36203402-4B33A16F-AC78-4E2B-9556-D5C771035CDB

Q36203402-523984F9-6A70-4C22-BB80-1465E1D7C809

Q36203402-557C82E2-5B72-497F-9151-D0D6AA4DB1BE

Q36203402-6A97D92D-368A-4B1B-89C0-49BD7BD85926

Q36203402-8459F536-3C21-4311-8BE2-E027F4FA9605

P304

Q36203402-FDCBB492-A3B0-461D-B93E-E03E4F596317

P31

Q36203402-3EEEFD00-2E45-4BEE-AD5B-55516B90B341

P356

Q36203402-7B5F6BE9-5CB5-477F-B83C-56DF46AB25F4

P433

Q36203402-1D97E7E6-1CAD-4E6F-829C-317EDE679624

P478

Q36203402-37B9761D-264A-40DD-8275-A3C06300FE53

P50

Q36203402-16296E13-9156-4069-BF50-37A23CB625EB

Q36203402-167ACE5C-9860-49E4-ACC7-B870569207AE

Q36203402-8AE09DC7-2697-4C9F-A176-070D8DC2E66F

P577

Q36203402-C13125BE-C720-4275-84FB-066C25CDB403

P698

Q36203402-65037961-295A-4507-80DB-E11B02C4E12E

P932

Q36203402-54748DEC-A0C2-4C2D-82DF-238B410BEAE1

P356

P1433

CPT: pharmacometrics & systems pharmacology

P1476

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

@en

P2093

B Weber

http://www.w3.org/2001/XMLSchema#string

C Zhou

http://www.w3.org/2001/XMLSchema#string

D R Mould

http://www.w3.org/2001/XMLSchema#string

E Comets

http://www.w3.org/2001/XMLSchema#string

E L Plan

http://www.w3.org/2001/XMLSchema#string

F Mentré

http://www.w3.org/2001/XMLSchema#string

I Freedman

http://www.w3.org/2001/XMLSchema#string

J John

http://www.w3.org/2001/XMLSchema#string

M O Karlsson

http://www.w3.org/2001/XMLSchema#string

M-S Mouksassi

http://www.w3.org/2001/XMLSchema#string

P2860

Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Data-based identifiability analysis of non-linear dynamical models.

Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.

STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN.

Automatic data binning for improved visual diagnosis of pharmacometric models.

Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.

Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.

A new equivalence based metric for predictive check to qualify mixed-effects models.

Diagnosing model diagnostics.

P304

87-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12161

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Andrew C. Hooker

J G Coen van Hasselt

Juan José Perez-Ruixo

P577

2016-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27884052

http://www.w3.org/2001/XMLSchema#string

P932

5321813

http://www.w3.org/2001/XMLSchema#string